‌

US Patent 11858941 Heterocyclic and heteroaryl compounds for treating Huntington's disease

Patent 11858941 was granted and assigned to PTC Therapeutics, Inc. on January, 2024 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

0

Patent attributes

Patent Applicant

PTC Therapeutics, Inc.

0

Current Assignee

PTC Therapeutics, Inc.

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Jigar Patel0

Anuradha Bhattacharyya0

Gary Mitchell Karp0

Anthony Turpoff0

Matthew G. Woll0

Jana Narasimhan0

Suresh Babu0

Guangming Chen0

...

Date of Patent

January 2, 2024

0

Patent Application Number

172546600

Date Filed

June 25, 2019

0

Patent Citations

US Patent 7473784 Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors

0

US Patent 6977255 Therapeutic morpholino-substituted compounds

0

US Patent 7326711 Pyridino[1,2-a]pyrimidin-4-one compounds as anticancer agents

0

US Patent 7399767 Heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors

0

US Patent 7569337 Coumarines useful as biomarkers

0

US Patent 7655657 Fused bicycloheterocycle substituted quinuclidine derivatives

0

US Patent 7897792 Coumarin derivative having antitumor activity

0

US Patent 7910578 8,10-diaza-bicyclo[4.3.1]decane derivatives and their medical use

0

...

Patent Primary Examiner

0

CPC Code

0

0

No article content yet.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11858941 Heterocyclic and heteroaryl compounds for treating Huntington's disease

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.